732 related articles for article (PubMed ID: 11959912)
1. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
[TBL] [Abstract][Full Text] [Related]
2. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.
Serradeil-Le Gal C; Wagnon J; Tonnerre B; Roux R; Garcia G; Griebel G; Aulombard A
CNS Drug Rev; 2005; 11(1):53-68. PubMed ID: 15867952
[TBL] [Abstract][Full Text] [Related]
3. Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415.
Stemmelin J; Lukovic L; Salome N; Griebel G
Neuropsychopharmacology; 2005 Jan; 30(1):35-42. PubMed ID: 15367924
[TBL] [Abstract][Full Text] [Related]
4. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.
Salomé N; Stemmelin J; Cohen C; Griebel G
Psychopharmacology (Berl); 2006 Aug; 187(2):237-44. PubMed ID: 16779555
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
Stemmelin J; Cohen C; Terranova JP; Lopez-Grancha M; Pichat P; Bergis O; Decobert M; Santucci V; Françon D; Alonso R; Stahl SM; Keane P; Avenet P; Scatton B; le Fur G; Griebel G
Neuropsychopharmacology; 2008 Feb; 33(3):574-87. PubMed ID: 17460614
[TBL] [Abstract][Full Text] [Related]
6. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
Griebel G; Stemmelin J; Gal CS; Soubrié P
Curr Pharm Des; 2005; 11(12):1549-59. PubMed ID: 15892661
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
[TBL] [Abstract][Full Text] [Related]
8. SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.
Breuer ME; van Gaalen MM; Wernet W; Claessens SE; Oosting RS; Behl B; Korte SM; Schoemaker H; Gross G; Olivier B; Groenink L
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):101-6. PubMed ID: 18668225
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.
Overstreet DH; Griebel G
Pharmacol Biochem Behav; 2005 Sep; 82(1):223-7. PubMed ID: 16181667
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.
Iijima M; Yoshimizu T; Shimazaki T; Tokugawa K; Fukumoto K; Kurosu S; Kuwada T; Sekiguchi Y; Chaki S
Br J Pharmacol; 2014 Jul; 171(14):3511-25. PubMed ID: 24654684
[TBL] [Abstract][Full Text] [Related]
11. The vasopressin V1b receptor as a therapeutic target in stress-related disorders.
Griebel G; Simiand J; Stemmelin J; Gal CS; Steinberg R
Curr Drug Targets CNS Neurol Disord; 2003 Jun; 2(3):191-200. PubMed ID: 12769799
[TBL] [Abstract][Full Text] [Related]
12. The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats.
Shimazaki T; Iijima M; Chaki S
Eur J Pharmacol; 2006 Aug; 543(1-3):63-7. PubMed ID: 16843459
[TBL] [Abstract][Full Text] [Related]
13. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders.
Griebel G; Simiand J; Steinberg R; Jung M; Gully D; Roger P; Geslin M; Scatton B; Maffrand JP; Soubrié P
J Pharmacol Exp Ther; 2002 Apr; 301(1):333-45. PubMed ID: 11907191
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.
Louis C; Cohen C; Depoortère R; Griebel G
Neuropsychopharmacology; 2006 Oct; 31(10):2180-7. PubMed ID: 16452986
[TBL] [Abstract][Full Text] [Related]
15. Effects of the vasopressin (V1b) receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, on FG 7142-induced increase in acetylcholine and norepinephrine release in the rat.
Claustre Y; Rouquier L; Desvignes C; Leonetti M; Montégut J; Aubin N; Allouard N; Bougault I; Oury-Donat F; Steinberg R
Neuroscience; 2006 Sep; 141(3):1481-8. PubMed ID: 16781820
[TBL] [Abstract][Full Text] [Related]
16. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
Alonso R; Griebel G; Pavone G; Stemmelin J; Le Fur G; Soubrié P
Mol Psychiatry; 2004 Mar; 9(3):278-86, 224. PubMed ID: 14699428
[TBL] [Abstract][Full Text] [Related]
17. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
Serradeil-Le Gal C; Wagnon J; Simiand J; Griebel G; Lacour C; Guillon G; Barberis C; Brossard G; Soubrié P; Nisato D; Pascal M; Pruss R; Scatton B; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 2002 Mar; 300(3):1122-30. PubMed ID: 11861823
[TBL] [Abstract][Full Text] [Related]
18. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A
Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
[TBL] [Abstract][Full Text] [Related]
19. Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice.
Amikishieva AV; Ilnitskaya SI; Nikolin VP; Popova NA
Exp Oncol; 2011 Sep; 33(3):126-9. PubMed ID: 21956463
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic social defeat on behavioral and neural correlates of sociality: Vasopressin, oxytocin and the vasopressinergic V1b receptor.
Litvin Y; Murakami G; Pfaff DW
Physiol Behav; 2011 Jun; 103(3-4):393-403. PubMed ID: 21397619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
